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Background: There is a growing body of evidence from critically-ill adults that standard doses of 
beta-lactams fail to achieve pharmacokinetic/pharmacodynamic (PK/PD) targets associated with 
successful treatment(1). Data is lacking for many antibiotics in children and neonates. We aimed to 
describe antibiotic PK and PK/PD target attainment in an age inclusive study (ABDose) of beta-
lactams in critically-ill adults, children and neonates.
Materials/methods: Study participants were adults, children and neonates admitted to intensive 
care and receiving one or more of eight beta-lactams as part of standard treatment. Following 
informed consent or assent, blood samples were obtained at predefined time-points between doses. 
Plasma was frozen at -80°C and concentrations were measured retrospectively using ultra-high-
performance liquid chromatography tandem mass spectrometry. Population-PK modelling was 
undertaken using non-linear mixed-effects modelling software (NONMEM v7.3, Icon plc). Minimum 
PK/PD targets of time with free concentration above the minimum inhibitory concentration (MIC) of 
the target pathogen (fT>MIC) at 50% and 100% of the dosing interval were used, alongside more 
conservative targets of concentration >4xMIC(1). Ethical approval was provided by the national 
research ethics committee, London (14/LO/1999).
Results: 216 participants (144 adults, 51 children, 21 neonates) provided 1283 samples for analysis. 
Allometric scaling and organ maturation functions were used to produce age inclusive 
pharmacokinetic models for each drug. The range of doses received by adults was greater than 
children and neonates, e.g. benzylpenicillin 10–34mg/kg adults vs 47–55mg/kg neonates (median 
17mg/kg vs 50mg/kg). Only 73% of antibiotic courses achieved 50%fT>MIC. There was marked 
heterogeneity in the %fT>MIC in adults (Figure 1). Paediatric participants were significantly less likely 
to achieve the lowest PK/PD target compared to adults (49% vs 74% achieving 50%fT>MIC, p<0.01 
Chi-squared). 
Conclusions: Current dosing regimens fail to achieve recognised PK/PD targets for a large 
proportion of critically ill patients. Children appear particularly vulnerable to under-dosing. The 
standard, “one size fits all” dosing in adults contributes to a failure to achieve PK/PD targets. To our 
knowledge, ABDose is the first study to demonstrate that antibiotic PK data from adults, children and 
neonates can be modelled simultaneously by using scaling and maturation functions. 
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